Novo's Ozempic® (Semaglutide) 2 MG Associated With Lower Risk Of Major Adverse Cardiovascular Events (Death

Novo Nordisk reported a real-world analysis finding lower cardiovascular risk when patients raised Ozempic to 2 mg versus switching to Mounjaro. Results were presented at the EASD Annual Meeting 2026 in Milan. * Study tracked adults with type 2 diabetes already using semaglutide 1 mg, reflecting common treatment intensification decisions in practice. Findings support dose escalation as a competitive positioning point against tirzepatide in cardiovascular outcomes for established semaglutide users. Safety outcomes were not evaluated in the analysis. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Nordisk A/S published the original content used to generate this news brief on September 29, 2026, and is solely responsible for the information contained therein. (C)